February 21st, 2023 | 14:11 CET
Russia's uranium business is booming! Cameco, GoviEx Uranium, RWE - How investors benefit
Since the outbreak of the Ukraine war, the West has imposed sanctions on the Russian energy sector. However, as evaluations by the London-based Royal United Services Institute (RUSI) and the Bloomberg news agency show, Russia's nuclear exports increased in 2022. While customers such as Ukraine and the Czech Republic would have stopped their imports from Russia, China, for example, would step into the breach. We look into what the situation on the uranium market means and how investors can achieve rich returns.
time to read: 3 minutes
|
Author:
Nico Popp
ISIN:
CAMECO CORP. | CA13321L1085 , GOVIEX URANIUM INC A | CA3837981057 , RWE AG INH O.N. | DE0007037129
Table of contents:
"[...] We have built one of the largest land packages of any non-producer in the belt at over 440 sq.km and have made more than 25 gold discoveries on the property to date with 5 of these discoveries totaling about 1.1 million ounces of gold resources. [...]" Jared Scharf, CEO, Desert Gold Ventures Inc.
Author
Nico Popp
At home in Southern Germany, the passionate stock exchange expert has been accompanying the capital markets for about twenty years. With a soft spot for smaller companies, he is constantly on the lookout for exciting investment stories.
Tag cloud
Shares cloud
Cameco: Uranium market remains tight
As RUSI and Bloomberg's research shows, China may have more than quadrupled its nuclear imports from Russia last year. While a total volume estimated at USD 450 million is not yet the world, other countries are believed to be importing more Russian uranium than before: for example, India, Turkey, and also Hungary. Although experts estimate Russian uranium business with foreign countries at only about USD 1 billion, the deals usually attract other deals, such as the construction of new nuclear power plants and related services.
Business with uranium is also booming outside Russia. Canadian industry leader Cameco exceeded analysts' expectations about a week ago: In the fourth quarter, the Company earned USD 0.09 per share, significantly more than analysts had expected (USD 0.05 per share). The outlook for the future was also positive: "We continue to believe that Cameco is the best choice to benefit from the recovery of the uranium market. With nuclear energy clearly back in sustained growth mode, Cameco is also back in sustained growth mode," said Cameco CEO Tim Gitzel.
GoviEx: Two advanced uranium projects promise high leverage
One company where growth could significantly outpace its peers is GoviEx Uranium. The Company has three uranium projects in Zambia, Niger and Mali. The first two projects already have mining permits. In total, the Company offers an indicated uranium resource of 130 million pounds of U3O8. In the inferred resource category, there is another 89 million pounds of U3O8. The Falea project in Mali offers copper, silver and gold in addition to uranium. In January, GoviEx signed a letter of intent to sell the property to African Energy Metals for CAD 5.5 million. The payment includes a cash component as well as shares in African Energy Metals and a 3% NSR.
GoviEx Uranium Inc. CEO Daniel Major on Feb 15, 2023 at the 6th IIF
"This is a strategic deal that will allow GoviEx shareholders to retain a significant interest in the Falea project while allowing the Company to focus on further exploration and development of its two uranium projects, Madaouela and Muntanga, which already have mine permits and are at an advanced stage," commented Daniel Major, CEO of GoviEx on the proposed transaction. Especially given the currently tight uranium market and the plans to build more nuclear power plants - for example, in Japan and China - GoviEx's focus on the two advanced projects should make sense. The share is currently anything but the focus of the market - for anti-cyclical investors and all those who already maintain a uranium watchlist, GoviEx is exceedingly exciting.
RWE: Nuclear power hardly plays a role anymore
Years ago, anyone who wanted to invest in nuclear power could bet on stocks like RWE. Today, E.ON and RWE warn of high hurdles in the event of continued operation of the power plants. Above all, they say, the supply of new fuel rods is a problem. The companies would also have to import uranium from other sources in the future instead of from Kazakhstan, Russia and, to a lesser extent, Canada. While the nuclear phase-out now seems unalterable for companies such as RWE and E.ON, countries such as Sweden, Japan, the USA and South Korea think quite differently and, in some cases, even want to build new nuclear reactors. Even within the EU, operating times are being extended, for example, in Belgium. The head of the International Energy Agency (IEA), Fatih Birol, believes nuclear power is already on the verge of a global comeback. At the same time, he warns countries like Germany that a departure from nuclear power could currently be the wrong decision. Nuclear power hardly plays a role for RWE at present: based on the figures for 2021, nuclear power and coal only account for 3.7% of sales. With this share, investors can hardly bet on a comeback of nuclear power.
That leaves stocks from countries in the former Soviet Union, such as Kazakhstan, or stocks like Cameco or GoviEX. While the former stocks are subject to political risks, Cameco, like Barrick Gold in precious metals, could offer limited opportunities given its high profile. Those who like it more speculative should definitely also focus on smaller stocks, such as GoviEx. Here, there is a chance to participate in two advanced uranium projects in Africa.
Conflict of interest
Pursuant to §85 of the German Securities Trading Act (WpHG), we point out that Apaton Finance GmbH as well as partners, authors or employees of Apaton Finance GmbH (hereinafter referred to as "Relevant Persons") may hold shares or other financial instruments of the aforementioned companies in the future or may bet on rising or falling prices and thus a conflict of interest may arise in the future. The Relevant Persons reserve the right to buy or sell shares or other financial instruments of the Company at any time (hereinafter each a "Transaction"). Transactions may, under certain circumstances, influence the respective price of the shares or other financial instruments of the Company.
In addition, Apaton Finance GmbH is active in the context of the preparation and publication of the reporting in paid contractual relationships.
For this reason, there is a concrete conflict of interest.
The above information on existing conflicts of interest applies to all types and forms of publication used by Apaton Finance GmbH for publications on companies.
Risk notice
Apaton Finance GmbH offers editors, agencies and companies the opportunity to publish commentaries, interviews, summaries, news and the like on news.financial. These contents are exclusively for the information of the readers and do not represent any call to action or recommendations, neither explicitly nor implicitly they are to be understood as an assurance of possible price developments. The contents do not replace individual expert investment advice and do not constitute an offer to sell the discussed share(s) or other financial instruments, nor an invitation to buy or sell such.
The content is expressly not a financial analysis, but a journalistic or advertising text. Readers or users who make investment decisions or carry out transactions on the basis of the information provided here do so entirely at their own risk. No contractual relationship is established between Apaton Finance GmbH and its readers or the users of its offers, as our information only refers to the company and not to the investment decision of the reader or user.
The acquisition of financial instruments involves high risks, which can lead to the total loss of the invested capital. The information published by Apaton Finance GmbH and its authors is based on careful research. Nevertheless, no liability is assumed for financial losses or a content-related guarantee for the topicality, correctness, appropriateness and completeness of the content provided here. Please also note our Terms of use.
